We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Major companies operating in the abrysvo or arexvy market are Pfizer Inc.; and GlaxoSmithKline plc GSK. These innovators have significantly contributed to the market growth and continue to propel ...

The suits allege that nanoparticles used in Moderna's Spikevax COVID-19 shot and recently approved mResvia vaccine for RSV – which competes with GSK's $1.7 billion blockbuster Arexvy ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "For the first time, all patients with primary advanced or recurrent endometrial cancer in the EU have an approved ...